Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12882326 | 1.00 | MEN1 (0.38) | MEN1KMT2APOLBSMN1; SMN2EPHX2 | |
| SCHEMBL13204288 | 0.93 | SHMT2 (0.36) | MEN1KMT2APOLBSMN1; SMN2EPHX2 | |
| SCHEMBL10114772 | 0.93 | SHMT2 (0.36) | MEN1KMT2APOLBSMN1; SMN2EPHX2 | |
| SCHEMBL10114758 | 0.89 | SHMT2 (0.39) | MEN1KMT2APOLBSMN1; SMN2GRIA2 | |
| SCHEMBL14424176 | 0.89 | SHMT2 (0.39) | MEN1KMT2APOLBSMN1; SMN2GRIA2 | |
| SCHEMBL10114386 | 0.87 | KDM4E (0.40) | MEN1KMT2ASMN1; SMN2GRIA2MAPT | |
| SCHEMBL10114735 | 0.87 | KDM4E (0.40) | MEN1KMT2ASMN1; SMN2GRIA2MAPT | |
| SCHEMBL10115609 | 0.85 | LMNA (0.37) | KMT2APOLBSMN1; SMN2MAPTLMNA | |
| SCHEMBL13204314 | 0.84 | MAPT (0.49) | MEN1KMT2ASMN1; SMN2EPHX2MAPT | |
| SCHEMBL10113964 | 0.84 | MAPT (0.49) | MEN1KMT2ASMN1; SMN2EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MEN1 2932/4885KMT2A 2768/4885POLB 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.